down arrow

Zhejiang Starry Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000026N8
  • SHG: 603520
CNY
8.66
0.05 (0.58%)

Sep 22

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Zhejiang Starry Pharmaceutical Co., Ltd.

Why is Zhejiang Starry Pharmaceutical Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 5.52%
  • The company has been able to generate a Return on Capital Employed (avg) of 5.52% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 11.49% and Operating profit at -27.16% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 6.49% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 11.49% and Operating profit at -27.16% over the last 5 years
4
Flat results in Jun 26
  • OPERATING CASH FLOW(Y) Lowest at CNY -12.47 MM
  • DEBT-EQUITY RATIO (HY) Highest at 105.86 %
  • RAW MATERIAL COST(Y) Grown by 21.79% (YoY)
5
With ROE of 0.65%, it has a expensive valuation with a 1.75 Price to Book Value
  • Over the past year, while the stock has generated a return of -25.00%, its profits have risen by 135.5% ; the PEG ratio of the company is 2
  • At the current price, the company has a high dividend yield of 2.3
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Zhejiang Starry Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Starry Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Zhejiang Starry Pharmaceutical Co., Ltd.
-22.4%
-0.35
43.59%
China Shanghai Composite
3.23%
0.23
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
11.49%
EBIT Growth (5y)
-27.16%
EBIT to Interest (avg)
1.88
Debt to EBITDA (avg)
7.99
Net Debt to Equity (avg)
0.88
Sales to Capital Employed (avg)
0.45
Tax Ratio
5.96%
Dividend Payout Ratio
1,287.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.57%
ROE (avg)
6.49%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
267
Industry P/E
Price to Book Value
1.75
EV to EBIT
97.79
EV to EBITDA
27.33
EV to Capital Employed
1.37
EV to Sales
2.89
PEG Ratio
1.97
Dividend Yield
2.29%
ROCE (Latest)
1.40%
ROE (Latest)
0.65%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
NET PROFIT(HY)

Higher at CNY 39.93 MM

-7What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at CNY -12.47 MM

DEBT-EQUITY RATIO (HY)

Highest at 105.86 %

RAW MATERIAL COST(Y)

Grown by 21.79% (YoY

CASH AND EQV(HY)

Lowest at CNY 595.72 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.69 times

Here's what is working for Zhejiang Starry Pharmaceutical Co., Ltd.

Net Profit
Higher at CNY 39.93 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Here's what is not working for Zhejiang Starry Pharmaceutical Co., Ltd.

Debt-Equity Ratio
Highest at 105.86 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Cash Flow
Lowest at CNY -12.47 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Cash and Eqv
Lowest at CNY 595.72 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio
Lowest at 3.69 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 21.79% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading